CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma

Inclusion Criteria: * Histologically confirmed mantle cell non-Hodgkin's lymphoma (MCL) * Relapsed, refractory, or stable disease after prior chemotherapy, radiotherapy, or immunotherapy * Unidimensionally measurable lymph node or lesion * At least 2.0 cm by CT scan or MRI OR at least 1.5 cm by physical exam * One of the following measurement parameters may be used: * Splenic enlargement may be used as a measurement parameter if spleen is palpable at least 3.0 cm across left costal margin * Malignant lymphocytosis may be used as a measurement parameter if absolute lymphocyte count is at least 5,000/mm\^3 * No known CNS involvement (parenchymal mass or leptomeningeal involvement) * Performance status - ECOG 0-2 * At least 3 months * See Disease Characteristics * Absolute neutrophil count ≥ 1,000/mm\^3 * Platelet count ≥ 75,000/mm\^3 * Hemoglobin ≥ 8 g/dL * Total bilirubin ≤ 1.5 times upper limit of normal (ULN) * Direct bilirubin ≤ 1.5 times ULN * AST ≤ 3 times ULN (5 times ULN if liver metastases are present) * Creatinine ≤ 2 times ULN * No symptomatic congestive heart failure * No unstable angina pectoris * No cardiac arrhythmia * Cholesterol ≤ 350 mg/dL * Triglycerides ≤ 400 mg/dL * HIV negative * No other active malignancy requiring treatment or that would preclude study participation * No other concurrent uncontrolled illness * No ongoing or active infection * No psychiatric illness or social situation that would preclude study participation * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 3 months after study participation * See Disease Characteristics * Prior high-dose therapy with stem cell transplantation allowed * At least 7 days since prior immunotherapy or other non-myelosuppressive biologic response modifiers * See Disease Characteristics * See Biologic therapy * At least 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas or mitomycin) * No other concurrent chemotherapy for MCL * Concurrent corticosteroids for adrenal insufficiency allowed * See Disease Characteristics * At least 3 weeks since prior radiotherapy * No concurrent radiotherapy for MCL * Any number of prior treatments allowed * No other concurrent investigational or commercial agents for MCL * No concurrent drugs that induce cytochrome p450 (e.g., carbamazepine, phenobarbital, phenytoin, ketoconazole, diltiazem, rifampin, terfenadine, cisapride, astemizole, or pimozide) * No concurrent immunosuppressive therapies